{
    "id": 31581,
    "fullName": "ABL1 T315M",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "ABL1 T315M lies within the protein kinase domain of the Abl1 protein (UniProt.org). T315M is associated with Abl1 inhibitor resistance in the context of BCR-ABL1 (PMID: 26511402, PMID: 31543464), demonstrates catalytic efficiency (kcat/km) similar to wild-type protein in an in vitro assay (PMID: 30684523), but has not been fully characterized and therefore, its effect on Abl1 protein function is unknown (PubMed, Feb 2020).",
            "references": [
                {
                    "id": 14163,
                    "pubMedId": 30684523,
                    "title": "The catalytic activity of Abl1 single and compound mutations: Implications for the mechanism of drug resistance mutations in chronic myeloid leukaemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30684523"
                },
                {
                    "id": 16762,
                    "pubMedId": 31543464,
                    "title": "Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31543464"
                },
                {
                    "id": 16766,
                    "pubMedId": 26511402,
                    "title": "Novel TKI-resistant BCR-ABL1 gatekeeper residue mutations retain in vitro sensitivity to axitinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26511402"
                },
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 25,
        "geneSymbol": "ABL1",
        "terms": [
            "ABL1",
            "ABL",
            "BCR-ABL",
            "bcr/abl",
            "c-ABL",
            "c-ABL1",
            "CHDSKM",
            "JTK7",
            "p150",
            "v-abl"
        ]
    },
    "variant": "T315M",
    "createDate": "11/13/2019",
    "updateDate": "02/05/2020",
    "referenceTranscriptCoordinates": {
        "id": 185530,
        "transcript": "NM_005157",
        "gDna": "chr9:g.130872896_130872897delCTinsTG",
        "cDna": "c.944_945delCTinsTG",
        "protein": "p.T315M",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 19205,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing ABL1 T315M in the context of BCR-ABL1 demonstrated resistance to Iclusing (ponatinib) in culture (PMID: 31543464).",
            "molecularProfile": {
                "id": 33952,
                "profileName": "BCR - ABL1 ABL1 T315M"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16762,
                    "pubMedId": 31543464,
                    "title": "Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31543464"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19204,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing ABL1 T315M in the context of BCR-ABL1 demonstrated resistance to Asciminib (ABL001) in culture (PMID: 31543464).",
            "molecularProfile": {
                "id": 33952,
                "profileName": "BCR - ABL1 ABL1 T315M"
            },
            "therapy": {
                "id": 2484,
                "therapyName": "Asciminib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16762,
                    "pubMedId": 31543464,
                    "title": "Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31543464"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19206,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Asciminib (ABL001) to treatment with Iclusig (ponatinib) resulted in restored efficacy and inhibition of BCR-ABL1 phosphorylation and proliferation in cells expressing ABL1 T315M in the context of BCR-ABL1 in culture (PMID: 31543464).",
            "molecularProfile": {
                "id": 33952,
                "profileName": "BCR - ABL1 ABL1 T315M"
            },
            "therapy": {
                "id": 8935,
                "therapyName": "Asciminib + Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16762,
                    "pubMedId": 31543464,
                    "title": "Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31543464"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 33951,
            "profileName": "ABL1 T315M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33952,
            "profileName": "BCR - ABL1 ABL1 T315M",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 185530,
            "transcript": "NM_005157",
            "gDna": "chr9:g.130872896_130872897delCTinsTG",
            "cDna": "c.944_945delCTinsTG",
            "protein": "p.T315M",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}